DOI QR코드

DOI QR Code

Clinical Application of Serum Tumor Abnormal Protein (TAP) in Colorectal Cancer Patients

  • Wu, Xue-Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research) ;
  • Huang, Xin-En (Department of Research, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research)
  • Published : 2015.04.29

Abstract

Objective: To explore the association of serum tumor abnormal protein (TAP) with other serological biomarkers e.g. carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9) and its clinical application in colorectal cancer (CRC) patients. Methods: Patients (N=98) were enrolled into this study with histologically or cytologically confirmed CRC. Using a test kit, the level of TAP was determined, while chemiluminescence was used to measure the levels of some other common serological biomarkers e.g. CEA, CA125 and CA19-9. Results: The area of TAP condensed particulate matter decreased after chemotherapy compared with before chemotherapy when CT or MRI scans showed disease control. In contrast, it increased with disease progression (P<0.05). Furthermore, a statistically significant difference was confirmed in monitoring of TAP and common serological biomarkers e.g. CEA and CA19-9 (p<0.05). Conclusions: Detecting TAP in CRC patients has high sensitivity and specificity and can be used as a new independent indicator for clinically monitoring CRC patients in the course of chemotherapy.

Keywords

Tumor abnormal protein (TAP);serological biomarkers;colorectal cancer (CRC)

References

  1. Bast RC Jr, Klug TL, St John E, et al (1983). A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 309, 883-7. https://doi.org/10.1056/NEJM198310133091503
  2. Brenner H, Kloor M, Pox CP (2014). Colorectal cancer. Lancet, 383, 1490-502. https://doi.org/10.1016/S0140-6736(13)61649-9
  3. Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006. https://doi.org/10.1038/cr.2008.282
  4. Coghlin C, Murray GI (2013). Progress in the identification of plasma biomarkers of colorectal cancer. Proteomics, 13, 2227-8. https://doi.org/10.1002/pmic.201300245
  5. Eleftheriadis N, Papaloukas C, Pistevou-Gompaki K (2009). Diagnostic value of serum tumor markers in asymptomatic individuals. J Buon, 14, 707-10.
  6. Elmunzer BJ, Hayward RA, Schoenfeld PS, et al (2012). Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med, 9, e1001352. https://doi.org/10.1371/journal.pmed.1001352
  7. Ferlay J, Shin HR, Bray F, et al ( 2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  8. Filella X, Molina R, Grau JJ, et al (1992). Prognostic value of CA 19-9 levels in colorectal cancer. Ann Surg, 216, 55-9. https://doi.org/10.1097/00000658-199207000-00008
  9. Gehan EA, Tefft MC (2000). Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst, 92, 179-81. https://doi.org/10.1093/jnci/92.3.179
  10. Goldberg EM, Simunovic LM, Drake SL, et al (1989). Comparison of serum ca 19-9 and cea levels in a population at high risk for colorectal cancer. Hybridoma, 8, 569-75. https://doi.org/10.1089/hyb.1989.8.569
  11. Grutzmann R, Molnar B, Pilarsky C, et al (2008). Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One, 3, e3759. https://doi.org/10.1371/journal.pone.0003759
  12. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008). Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol, 103, 1541-9. https://doi.org/10.1111/j.1572-0241.2008.01875.x
  13. Huang XE, Cao J, Qian ZY, et al (2014). Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Asian Pac J Cancer Prev, 15, 8495-7. https://doi.org/10.7314/APJCP.2014.15.19.8495
  14. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26. https://doi.org/10.1002/ijc.25007
  15. Jemal A, Bray F, CenterMMet al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  16. Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. https://doi.org/10.7314/APJCP.2014.15.20.8603
  17. Kim HJ, Yu MH, Kim H, Byun J, Lee C (2008). Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep, 41, 685-92. https://doi.org/10.5483/BMBRep.2008.41.10.685
  18. Lee BB, Lee EJ, Jung EH, et al (2009). Aberrant methylation of APC, MGMT, RASSF2A, and Wif1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res, 15, 6185-91. https://doi.org/10.1158/1078-0432.CCR-09-0111
  19. Li YH, An X, Xiang XJ (2009). Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy [in Chinese]. Ai Zheng, 28, 939-44.
  20. Liu J, Huang XE (2014). Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation. Asian Pac J Cancer Prev, 15, 10241-4.
  21. Lu YY, Huang XE, et al (2014). Clinical observations on associations between the UGT1A1 genotype and severe toxicity of irinotecan. Asian Pac J Cancer Prev, 15, 3335-41. https://doi.org/10.7314/APJCP.2014.15.7.3335
  22. Luo Y, Wang L, Wang J (2013). Developing proteomicsbased biomarkers for colorectal neoplasms for clinical practice:opportunities and challenges. Proteomics Clin Appl, 7, 30-41. https://doi.org/10.1002/prca.201200071
  23. Martínez-Aguilar J, Chik J, Nicholson J, et al (2013). Quantitative mass spectrometry for colorectal cancer proteomics. Proteomics Clin Appl, 7, 42-54. https://doi.org/10.1002/prca.201200080
  24. McKeown E, Nelson DW, Johnson EK, et al (2014). Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer, 5, 31-43 https://doi.org/10.7150/jca.7987
  25. Migliore L, Migheli F, Spisni R, Coppede F (2011). Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol, 2011, 792362.
  26. Newton KF, Newman W, Hill J (2012). Review of biomarkers in colorectal cancer. Colorectal Dis, 14, 3-17.
  27. Perkins GL, Slater ED, Sanders GK, et al (2003). Serum tumor markers. Am Fam Physician, 68, 1075-82.
  28. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  29. Sorbye H, Dahl O (2004). Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol, 43, 495-8. https://doi.org/10.1080/02841860410032380
  30. Tian GY, Miu M, Huang XE (2014). Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev, 15, 8475-8. https://doi.org/10.7314/APJCP.2014.15.19.8475
  31. Wang L, Huang XE (2015). Clinical study on safety and efficacy of JiSaiXin (recombinant human granulocyte colony stimulating factor injection manufactured in China) for Chinese undergoing chemotherapy. Asian Pac J Cancer Prev, 16 299-301. https://doi.org/10.7314/APJCP.2015.16.1.299
  32. Winawer S, Fletcher R, Rex D, et al (2003). Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology, 124, 544-60. https://doi.org/10.1053/gast.2003.50044
  33. Wu XY, Huang XE (2015). Screening for patients with non-small cell lung cancer who could survive long term chemotherapy. Asian Pac J Cancer Prev, 16, 647-52. https://doi.org/10.7314/APJCP.2015.16.2.647
  34. Wu XY, Huang XE, et al (2014). A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer. Asian Pac J Cancer Prev, 15, 5941-4. https://doi.org/10.7314/APJCP.2014.15.14.5941
  35. Xu D, Li XF, Zheng S, Jiang WZ (2006). Quantitative real-time RTPCR detection for CEA, CK20 and CK19 mRNA in peripheral blood of colorectal cancer patients. J Zhejiang Univ Sci, B7, 445-51.
  36. Yang L, Sun Y, Huang XE, Yu DS, et al (2015). Carcinoma Microsatellite Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Stage II Rectal Cancer. Asian Pac J Cancer Prev, 16, 1545-51. https://doi.org/10.7314/APJCP.2015.16.4.1545
  37. Zieglschmid V, Hollmann C, Bocher O (2005). Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci, 42, 155-96. https://doi.org/10.1080/10408360590913696

Cited by

  1. Diet and Colorectal Cancer Risk in Asia - a Systematic Review vol.16, pp.13, 2015, https://doi.org/10.7314/APJCP.2015.16.13.5389
  2. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  3. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485
  4. Prognostic value of serum tumor abnormal protein in gastric cancer patients vol.5, pp.1, 2016, https://doi.org/10.3892/mco.2016.877